combining tirzepatide and retatrutide vs — What to Know Before You Decide combining tirzepatide and semaglutide Comparing

Description

New trial data for Amgen's GLP-1 drug MariTide shows a weight loss of 20 percent in non-diabetic participants with obesity or overweight.

Even though demand for peptide therapies has exploded since then, theres been little new science.

Individualization is Key: The ADA strongly advocates tailoring HbA1c goals based on: Duration of diabetes Risk of hypoglycemia Life expectancy Comorbidities (cardiovascular disease, CKD) Patient preference and treatment burden Beyond HbA1c: Modern diabetes care increasingly integrates Continuous Glucose Monitoring (CGM) metrics such as Time in Range (TIR) alongside HbA1c